Narcotic analgesics Market Report 2021: By Key Players, Application, Type, Share and Forecast 2021-2027

The Global Non-narcotic analgesics market is estimated to grow at a significant CAGR during the forecast period. Non-opioid analgesics are drugs used to relieve pain; however, because most opioid drugs are misused at some point by patients or other people for non-medical purposes, the use of opioid drugs is suggested to be lowered by many healthcare professionals. Non-narcotic analgesics are pain and inflammation-controlling drugs. A non-narcotic drug is one that has antipyretic, analgesic, and anti-inflammatory properties. Non-narcotic analgesics have no effect on opioid receptors. Some of these drugs can be used during surgery to decrease post-operative pain, and reduce the need for narcotics.

A full report of Narcotic analgesics Market is available at: https://www.omrglobal.com/industry-reports/non-narcotic-analgesics-market

The rising incidence of chronic diseases such as cancer, where different therapies such as chemotherapy are to responsible for pain, is expected to fuel the expansion of the non-opioid analgesics market. The rising number of surgeries is expected to increase the prevalence of post-operative pain, driving the expansion of the non-opioid analgesics market. The growing number of persons suffering neuropathic pain is expected to fuel the expansion of the non-opioid analgesics industry. According to NCBI, Non-narcotic analgesics are effectiveness for a wide spectrum of pain and inflammatory disorders, non-opioid analgesics are among the most commonly used medicines. Over 172 million prescriptions for cyclooxygenase (COX) inhibitors (both selective and non-selective) were issued in the United States alone.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/non-narcotic-analgesics-market

In June 2019, Ironwood Pharmaceuticals and Allergan started treating patients in a Phase II Clinical Trial of MD-7246 in individuals with irritable bowel syndrome and diarrhoea (IBS-D). The drug is being tested as an oral, intestinal, non-opioid pain reliever for individuals with abdominal pain caused by gastrointestinal disorders.

In June 2018, Sandoz Canada announced a collaboration with Tilray, a Health Canada-licensed medical cannabis producer, to become the first Canadian pharmaceutical firm to enter the medical cannabis sector.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment covered

o             By Type

o             By Application

  • Region covered

o             North America

o             Europe

o             Asia-Pacific

o             Rest of the world

  • Competitive Landscape- Akron, Inc., BioDelivery Sciences International, Inc., Endo Pharmaceuticals., GlaxoSmithKline PLC., Novartis AG., Pfizer., Sanofi S.A, and Teva Pharmaceuticals., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o             Recovery Timeline

o             Deviation from pre-COVID forecast

o             Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Market Segmentation

By Type

  • Non Steroid Anti – inflammatory Drug
  • Steroid Anti – inflammatory Drug

By Application

  • Hospital
  • Medical Center
  • Others

Company Profiles

  • Akron, Inc.
  • BioDelivery Sciences International, Inc.
  • Endo Pharmaceuticals.
  • GlaxoSmithKline PLC.
  • Novartis AG.
  • Sanofi S.A
  • Teva Pharmaceuticals

This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.

Leave a Reply

Your email address will not be published. Required fields are marked *